文章基本信息

标题：Field cancerization profile-based prognosis signatures lead to more robust risk evaluation in hepatocellular carcinoma
本地全文：下载
作者：Lu Huang ; Zhou Songyang ; Zhiming Dai 等
期刊名称：iScience
印刷版ISSN：2589-0042
出版年度：2022
卷号：25
期号：2
页码：1-23
DOI：10.1016/j.isci.2022.103747
语种：English
出版社：Elsevier
摘要：SummaryThe development of reliable biomarkers has been an urgent issue as well as a hot spot of research on the diagnosis, treatment, and prognostic evaluation of hepatocellular carcinoma (HCC). Here, we established and validated two field cancerization profile-based prognostic signatures (gene expression score [GES] and immune score [IS]) for HCC. Our study confirmed that field cancerization profile-based models outperform conventional models on risk evaluation, offering insights for further studies on prognostic model construction. The nomogram constructed by combining GES, IS, and TNM stage was proved effective in improving the individualized prediction of the overall risk of patients. Distinct peritumoral characteristics were observed in several immune cells (e.g., CD8 T cells and dendritic cells), which might explain the diversified prognosis and clinical benefit of immunotherapy. Moreover, a series of drug targets, prognosis-associated genes, and pathways were identified, which may contribute to molecular mechanism studies as well as therapeutic target development of HCC.Graphical abstractDisplay OmittedHighlights•Two field cancerization feature-based prognostic signatures for HCC were developed•Joint nomogram is effective in improving individualized risk prediction•Different peritumor signatures were observed in several immune cells•Several peritumoral drug targets, prognostic genes, and pathways were identifiedBioinformatics; Expression study; Omics